For: | Ge WS, Fan JG. Integrin antagonists are effective and safe for Crohn’s disease: A meta-analysis. World J Gastroenterol 2015; 21(15): 4744-4749 [PMID: 25914486 DOI: 10.3748/wjg.v21.i15.4744] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i15/4744.htm |
Number | Citing Articles |
1 |
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen, A Barney Hawthorne. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68(Suppl 3): s1 doi: 10.1136/gutjnl-2019-318484
|
2 |
Seana ML Nelson, Tran M Nguyen, John WD McDonald, John K MacDonald. Natalizumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2018; 2018(8) doi: 10.1002/14651858.CD006097.pub3
|
3 |
Peijian He, Abedul Haque, Songbai Lin, Fabio Cominelli, C. Chris Yun. Inhibition of autotaxin alleviates inflammation and increases the expression of sodium-dependent glucose cotransporter 1 and Na+/H+ exchanger 3 in SAMP1/Fc mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 2018; 315(5): G762 doi: 10.1152/ajpgi.00215.2018
|
4 |
Doreen E. Szollosi, Kirsten Hokeness, Mohammed K. Manzoor. Pharmacology of Immunotherapeutic Drugs. 2020; : 207 doi: 10.1007/978-3-030-19922-7_7
|
5 |
Subrata Ghosh, Brian Bressler, Jill Petkau, Roopal B. Thakkar, Song Wang, Martha Skup, Jingdong Chao, Remo Panaccione, Stefan Schreiber. Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease. Digestive Diseases and Sciences 2019; 64(5): 1142 doi: 10.1007/s10620-018-5419-3
|